European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
- Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC)
The combination significantly improved overall survival (OS) and progression-free survival (PFS) for the first time in over 20 years
Basel, 6 September 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved and granted marketing authorisation for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
“This approval makes Tecentriq the first cancer immunotherapy available in Europe for the initial treatment of extensive-stage small cell lung cancer, marking an important step forward for patients,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “The combination of Tecentriq and chemotherapy has been shown to improve survival compared to the current standard-of-care – an advance that, until now, has been difficult to achieve due to the refractory nature of this disease.”
This approval is based on results from the Phase III IMpower133 study, which showed that Tecentriq in combination with chemotherapy helped people live significantly longer compared with chemotherapy alone (median overall survival [OS]=12.3 versus 10.3 months; hazard ratio [HR]=0.70, 95% CI: 0.54–0.91; p=0.0069) in the intention-to-treat (ITT) population. The Tecentriq-based combination also significantly reduced the risk of disease worsening or death (progression-free survival [PFS]) compared with chemotherapy alone (PFS=5.2 versus 4.3 months; HR=0.77; 95% CI, 0.62–0.96; p=0.017).1 Safety for the Tecentriq and chemotherapy combination appeared consistent with the known safety profile of Tecentriq.
Lung cancer is the leading cause of cancer death worldwide2 and SCLC accounts for approximately 15% of all lung cancer cases, with the majority of patients (70%) diagnosed in the “extensive stage”, often meaning a poor prognosis.3 SCLC is distinguished from other lung cancer subtypes due to its aggressive nature, rapid growth, and early development of metastatic disease.3
Currently, Roche has nine Phase III lung cancer studies underway evaluating Tecentriq alone or in combination with other medicines across different types of lung cancer. Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies, across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.
About the IMpower133 study
IMpower133 is a Phase III, multicentre, double-blinded, randomised placebo-controlled study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and etoposide) versus chemotherapy (carboplatin and etoposide) alone in chemotherapy-naïve adults with ES-SCLC.
The study enrolled 403 people who were randomised equally (1:1) to receive:
- Tecentriq in combination with carboplatin and etoposide (Arm A), or
- Placebo in combination with carboplatin and etoposide (Arm B, control arm)
During the treatment-induction phase, people received treatment on 21-day cycles for four cycles, followed by maintenance with Tecentriq or placebo until progressive disease (PD), as assessed by the investigator using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1). Treatment could be continued until persistent radiographic PD or symptomatic deterioration was observed.
The co-primary endpoints were PFS, as determined by the investigator using RECIST v1.1, and OS in the ITT population.
A summary of the ITT data from the IMpower133 study that support this approval is included below:1
- Tecentriq in combination with chemotherapy helped people live significantly longer, compared with chemotherapy alone (OS=12.3 versus 10.3 months; HR=0.70, 95% CI: 0.54-0.91, p=0.0069) in the ITT population.
- The Tecentriq-based combination also significantly reduced the risk of disease worsening or death compared with chemotherapy alone (PFS=5.2 versus 4.3 months; HR=0.77; 95% CI: 0.62–0.96, p=0.017).
- Safety for the Tecentriq and chemotherapy combination appeared consistent with the known safety profile of Tecentriq.
- Grade 3–4 treatment-related adverse events occurred in 56.6% of people receiving Tecentriq plus chemotherapy, compared with 56.1% of people receiving chemotherapy alone. The most common adverse reactions (≥20%) in people receiving Tecentriq plus chemotherapy were low white blood cell count (neutropenia; 23%), anaemia (14%), decreased neutrophil count (14%) and thrombocytopenia (10%).
Lung cancer is the leading cause of cancer death globally.2 Each year 1.76 million people die as a result of the disease; this translates into more than 4,800 deaths worldwide every day.2 Lung cancer can be broadly divided into two major types: NSCLC and SCLC, with SCLC accounting for approximately 15% of all lung cancer cases.3
About Tecentriq (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T cells. Tecentriq is a cancer immunotherapy (CIT) that has the potential to be used as a foundational combination partner with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. The development of Tecentriq and its clinical programme is based on our greater understanding of how the immune system interacts with tumours and how harnessing a person’s immune system combats cancer more effectively.
Tecentriq is approved in the US, EU and countries around the world, either alone or in combination with targeted therapies and/or chemotherapies in various forms of non-small cell and small cell lung cancer, certain types of metastatic urothelial cancer, and in PD-L1-positive triple-negative breast cancer.
About Roche in cancer immunotherapy
For more than 50 years, Roche has been developing medicines with the goal to redefine treatment in oncology. Today, we’re investing more than ever in our effort to bring innovative treatment options that help a person’s own immune system fight cancer.
By applying our seminal research in immune tumour profiling within the framework of the Roche-devised cancer immunity cycle, we are accelerating and expanding the transformative benefits with Tecentriq to a greater number of people living with cancer. Our cancer immunotherapy development programme takes a comprehensive approach in pursuing the goal of restoring cancer immunity to improve outcomes for patients.
To learn more about the Roche approach to cancer immunotherapy please follow this link:
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
 Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379: 2220–2229
 World Health Organization. GLOBOCAN 2018; Lung Cancer: Estimated cancer incidence, mortality and prevalence worldwide. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed August 2019.
 Paglialunga L et al. Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO Open 2016;1:e000022.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Daniel Grotzky
- Karsten Kleine
- Nathalie Meetz
- Barbara von Schnurbein
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
DNO ASA: Mandatory Notification of Trade17.9.2019 16:56:00 CEST | Press release
Oslo, 17 September 2019 - DNO ASA, the Norwegian oil and gas operator, has today purchased 1,800,000 own shares at an average price of NOK 14.3560 per share. Following this transaction, DNO holds 45,000,000 own shares. -- For further information, please contact: Media: email@example.com Investors: firstname.lastname@example.org -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Banks net position in the Riksbank17.9.2019 16:42:00 CEST | Press release
SEP 17, 2019 SEK MILLION LENDING BORROWING 348
Vostok Emerging Finance investerar i Xerpa, brasiliens ledande HR-plattform och löneutjämningsprodukt.17.9.2019 15:00:00 CEST | Pressemelding
Stockholm, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Vostok Emerging Finance (“VEF”) meddelade idag att bolaget har investerat 8.5 MUSD i Xerpa, brasiliens ledande HR-plattform och leverantör av Xerpay, bolagets löneutjämningsprodukt. VEF ledde Serie B-finansieringsrundan om totalt 13 MUSD, i vilken även Founders Fund (den första institutionella investeraren i Facebook and SpaceX) ledd av Peter Thiel, en av PayPals grundare, deltog tillsammans med de befintliga investerarna Kaszek Ventures, Redpoint e.ventures och QED. Genom denna investering äger VEF en minoritetspost och har styrelserepresentation i bolaget. Xerpa’s löneutjämningsprodukt, Xerpay, ger löntagare åtkomst till sin redan intjänade lön, omgående och vid vilken tidpunkt som helst, likt Wafestream i Storbritannien. Brasilien har länge lidit av några av världens högsta räntor, låg andel finansiellt inkluderade individer och 60% av arbetstagarna kämpar för att få lönen att räcka månaden ut. Genom Xerpay får löntagare omedelbar finans
Vostok Emerging Finance invests into Xerpa, Brazil’s leading HR platform and salary-on-demand provider.17.9.2019 15:00:00 CEST | Press release
Stockholm, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Vostok Emerging Finance (“VEF”) announces its USD 8.5 mln investment into leading Brazilian HR platform and salary-on-demand provider, Xerpa. VEF led a broader Series B investment round of USD 13 mln and is joined by Founders Fund (the first institutional investor in Facebook and SpaceX) led by Peter Thiel, one of the founders of PayPal, alongside existing investors, Kaszek Ventures, Redpoint e.ventures and QED. Post the transaction VEF holds a minority stake and board representation in the company. Xerpa’s salary-on-demand product, Xerpay, allows employees to access their already earned wages, instantly and at any time, similar to Wagestream in the UK. Brazil has long suffered from some of the highest interest rates globally, poor financial inclusion and 60% of workers struggle to make their paycheck last the month. Through Xerpay, employees gain instant financial security and thus can avoid the cumulative spiral of debt, defaults and pena
Prosafe SE: Mandatory notification of trade17.9.2019 14:38:00 CEST | Press release
Jesper K. Andresen, Chief Executive Officer, has on 17 September 2019 purchased 51,591 shares in Prosafe SE at an average price of NOK 9.602 per share. Following the transaction, Jesper K. Andresen owns 84,067 shares in Prosafe SE. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The Company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 17 September 2019 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig H. Christiansen, Deputy CEO and CFO Phone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Sampo plc: Managers’ Transactions (Martinsen)17.9.2019 14:35:00 CEST | Press release
SAMPO PLC MANAGERS’ TRANSACTIONS 17 September 2019 at 3:35 pm Sampo plc: Managers’ Transactions (Martinsen) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation. Shares have been acquired in accordance with terms and conditions of the long-term incentive scheme 2014. ____________________________________________ Person subject to the notification requirement Name: Martinsen, Ivar Position: Other senior manager Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: INITIAL NOTIFICATION Reference number: 743700UF3RL386WIDA22_20190917122147_10 ____________________________________________ Transaction date: 2019-09-13 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION Transaction details (1): Volume: 1,770 Unit price: 38.1824 EUR Aggregated transactions (1): Volume: 1,770 Volume weighted average price: 38.1824 EU